IP Library Granted Patent US 12,590,084
Granted Patent B2
US 12,590,084 · App. 18/132,216 · Granted Mar 31, 2026

Oxadiazole HDAC6 inhibitors and uses thereof

Inventors: Florence Fevrier Wagner (Ashland, MA); Thomas Edward Richardson (Cary, NC)
Assignee: Eikonizo Therapeutics, Inc.
C07D413/04A61K31/4439A61K31/444A61K31/4709A61K31/4725A61K31/498A61K31/4985A61K31/501A61K31/506A61K31/517A61K31/519A61K31/5377A61K31/5386C07D413/14C07D471/04C07D487/04C07D498/04C07D498/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,590,084
App. No.
18/132,216
Granted
Mar 31, 2026
Kind
B2
Abstract

Provided herein are compounds that selectively inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.

Claims (57)

1 . A compound of Formula (I):

or a pharmaceutically acceptable salt thereof,

wherein:

X is CR 1 or N; Y is CR 1 or N; provided that at least one of X and Y is N;

R 1 is hydrogen or halogen;

R a and R b are each independently hydrogen or halogen;

L is a bond;

A is a 5-membered heteroaryl, wherein A is optionally substituted with one or more substituents R 2 ; and

each occurrence of R 2 is independently halogen, substituted or unsubstituted amin-o, substituted or unsubstituted amido, cyano, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted heterocyclyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

2 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R a and R b are each independently hydrogen or fluoro.

3 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein X is N and Y is CH, CF, or N.

4 . The compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein

each occurrence of R 2 is independently halogen, amino, substituted amino, amido, cyano, C 1-4 alkyl, C 1-4 haloalkyl, C 2-4 alkenyl, C 2-4 alkynyl, heteroC 2-4 alkyl, heteroC 2-4 alkenyl, heteroC 2-4 alkynyl, 3-6 membered heterocyclic, C 3-6 carbocyclyl, C 6-14 aryl, or 5-10 membered heteroaryl;

wherein the amino, amido, 3-6 membered heterocyclic, C 3-6 carbocyclyl, C 6-14 aryl, or 5-10 membered heteroaryl in each R 2 is each optionally substituted with one or more halogen, C 1-4 alkyl, or C 1-4 haloalkyl.

5 . The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein each occurrence of R 2 is independently halogen, amino, substituted amino, amido, cyano, C 1-4 alkyl, C 1-4 haloalkyl, C 2-4 alkenyl, C 2-4 alkynyl, heteroC 2-4 alkyl, heteroC 2-4 alkenyl, or heteroC 2-4 alkynyl; and the amino or amido in each R 2 is each optionally substituted with one or more halogen, C 1-4 alkyl, or C 1-4 haloalkyl.

6 . The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein each occurrence of R 2 is independently C 1-4 alkyl, cyano, 3-6 membered heterocyclic, or C 3-6 carbocyclyl.

7 . The compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein A is optionally substituted with 1-3 substituents of R 2 ; and wherein A is:

a. pyrrolyl, furanyl, or thiophenyl;

b. imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl; or

c. triazolyl, oxadiazolyl, or thiadiazolyl.

8 . The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein each occurrence of R 2 is independently C 1-4 alkyl, C 1-4 haloalkyl, cyano, 3-6 membered heterocyclic, or C 3-6 carbocyclyl.

9 . The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein A is a diazole or thiophenyl and A is optionally substituted with one R 2 .

10 . The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein each occurrence of R 2 is independently methyl, ethyl, cyano or tetrahydropyran.

11 . The compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein A is

12 . The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

13 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

14 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

15 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

16 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

17 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

18 . A compound of Formula (I):

or a pharmaceutically acceptable salt thereof,

wherein:

X is N; Y is CH, CF, or N;

R a and R b are each hydrogen;

L is a bond;

A is a 5-membered heteroaryl, wherein A is optionally substituted with one or more substituents R 2 ; and

each occurrence of R 2 is independently C 1-4 alkyl, cyano, 4-6 membered heterocyclic, or C 3-6 carbocyclyl.

19 . A compound of Formula (I):

or a pharmaceutically acceptable salt thereof,

wherein:

X is CR 1 or N; Y is CR 1 or N;

wherein:

R 1 is H or halogen;

provided that at least one of X and Y is N;

R a and R b are each independently hydrogen or halogen;

L is a bond;

A is a phenyl, pyridinyl or pyrimidinyl, wherein A is substituted with one substituent R 2 ; and

wherein R 2 is C 6-14 aryl, or 5-10 membered heteroaryl; and wherein the C 6-14 aryl, or 5-10 membered heteroaryl as defined for R 2 is optionally substituted with one or more C 1-4 alkyl.

20 . The compound of claim 19 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2023
From: WAGNER, FLORENCE FEVRIER; RICHARDSON, THOMAS EDWARD
To: EIKONIZO THERAPEUTICS, INC.
Reel/Frame 065391/0817 →
Continuity (2)
Provisional Application 63329143 · Apr 8, 2022
Related Publication 20230322747A1 · Oct 12, 2023
References Cited (400)
US 4205085A · Shepherd · 1980 [cited by applicant]
US 5231097A · Klausener et al. · 1993 [cited by applicant]
US 5272158A · Hartman et al. · 1993 [cited by applicant]
US 5686018A · Demus et al. · 1997 [cited by applicant]
US 5728844A · Muller et al. · 1998 [cited by applicant]
US 5728845A · Muller et al. · 1998 [cited by applicant]
US 8778931B2 · Gould · 2014 [cited by applicant]
US 9096518B2 · Blackburn et al. · 2015 [cited by applicant]
US 9145405B2 · Luo et al. · 2015 [cited by applicant]
US 9650379B2 · Lee et al. · 2017 [cited by applicant]
US 10272084B2 · Kavelaars et al. · 2019 [cited by applicant]
US 10357493B2 · Yates · 2019 [cited by applicant]
US 10774179B2 · Kember et al. · 2020 [cited by applicant]
US 11066396B2 · Walji et al. · 2021 [cited by applicant]
US 11938134B2 · Yates · 2024 [cited by applicant]
US 12370194B2 · Yates et al. · 2025 [cited by applicant]
US 20050165015A1 · Ncube et al. · 2005 [cited by applicant]
US 20060052599A1 · Ishibashi et al. · 2006 [cited by applicant]
US 20060142321A1 · Jover et al. · 2006 [cited by applicant]
US 20060142332A1 · Torrens Jover et al. · 2006 [cited by applicant]
US 20080214603A1 · Torrens Jover et al. · 2008 [cited by applicant]
US 20090036480A1 · Torrens Jover et al. · 2009 [cited by applicant]
US 20090074717A1 · Leivers et al. · 2009 [cited by applicant]
US 20090197880A1 · Leivers et al. · 2009 [cited by applicant]
US 20090247757A1 · Li et al. · 2009 [cited by applicant]
US 20100130499A1 · Tafesse · 2010 [cited by applicant]
US 20110039827A1 · Blackburn et al. · 2011 [cited by applicant]
US 20110212969A1 · Blackburn et al. · 2011 [cited by applicant]
US 20110251184A1 · Blackburn et al. · 2011 [cited by applicant]
US 20110288117A1 · Gould et al. · 2011 [cited by applicant]
US 20120040953A1 · Barba et al. · 2012 [cited by applicant]
US 20120094997A1 · England et al. · 2012 [cited by applicant]
US 20120202834A1 · Aspnes et al. · 2012 [cited by applicant]
US 20140275093A1 · Blackburn et al. · 2014 [cited by applicant]
US 20140329825A1 · Hebach et al. · 2014 [cited by applicant]
US 20150197497A1 · Abeywickrama et al. · 2015 [cited by applicant]
US 20150359794A1 · Benz et al. · 2015 [cited by applicant]
US 20160039789A1 · England et al. · 2016 [cited by applicant]
US 20170096405A1 · Song et al. · 2017 [cited by applicant]
US 20170183325A1 · Chen et al. · 2017 [cited by applicant]
US 20170313698A1 · Shuttleworth et al. · 2017 [cited by applicant]
US 20170349540A1 · Hooker et al. · 2017 [cited by applicant]
US 20180215743A1 · Lee et al. · 2018 [cited by applicant]
US 20180256572A1 · Yates · 2018 [cited by applicant]
US 20180273495A1 · Kim et al. · 2018 [cited by applicant]
US 20190077786A1 · Ueng et al. · 2019 [cited by applicant]
US 20190135799A1 · Ito et al. · 2019 [cited by applicant]
US 20200171028A1 · Yates · 2020 [cited by applicant]
US 20210188831A1 · Lee et al. · 2021 [cited by applicant]
US 20220041584A1 · Piscopio et al. · 2022 [cited by applicant]
US 20220088018A1 · Yates · 2022 [cited by applicant]
US 20220098180A1 · Ito et al. · 2022 [cited by applicant]
US 20220144815A1 · Brunet et al. · 2022 [cited by applicant]
US 20220251043A1 · Pan et al. · 2022 [cited by applicant]
US 20220281814A1 · Wagner et al. · 2022 [cited by applicant]
US 20230322747A1 · Wagner · 2023 [cited by applicant]
US 20240307391A1 · Yates · 2024 [cited by applicant]
US 20250230166A1 · Wagner · 2025 [cited by applicant]
US 20250250263A1 · Wagner et al. · 2025 [cited by applicant]
CN 101573333A · 2009 [cited by applicant]
CN 105884767A · 2016 [cited by applicant]
CN 108976223A · 2018 [cited by applicant]
CN 109651357A · 2019 [cited by applicant]
CN 110950860A · 2020 [cited by applicant]
CN 112794860A · 2021 [cited by applicant]
DE 3929233A1 · 1991 [cited by applicant]
DE 4029466A1 · 1991 [cited by applicant]
DE 4307243A1 · 1993 [cited by applicant]
DE 10312963A1 · 2004 [cited by applicant]
EP 540334A1 · 1993 [cited by applicant]
EP 625513A1 · 1994 [cited by applicant]
EP 2624832B1 · 2017 [cited by applicant]
JP S58170780A · 1983 [cited by applicant]
JP H04272989A · 1992 [cited by applicant]
JP H07206829A · 1995 [cited by applicant]
JP H10251255A · 1998 [cited by applicant]
JP 2002305083A · 2002 [cited by applicant]
JP 20118205A · 2011 [cited by applicant]
JP 2011148714A · 2011 [cited by applicant]
JP 2013542994A · 2013 [cited by applicant]
JP 2017190296A · 2017 [cited by applicant]
WO WO199511228A1 · 1995 [cited by applicant]
WO WO1997040017A2 · 1997 [cited by applicant]
WO WO199845268A1 · 1998 [cited by applicant]
WO WO1999019419A1 · 1999 [cited by applicant]
WO WO2000015637A1 · 2000 [cited by applicant]
WO WO2000068230A1 · 2000 [cited by applicant]
WO WO2001072712A1 · 2001 [cited by applicant]
WO WO2001085695A1 · 2001 [cited by applicant]
WO WO2002002530A1 · 2002 [cited by applicant]
WO WO2002026696A1 · 2002 [cited by applicant]
WO WO2002026703A1 · 2002 [cited by applicant]
WO WO2002030879A2 · 2002 [cited by applicant]
WO WO2002098426A1 · 2002 [cited by applicant]
WO WO2003024448A2 · 2003 [cited by applicant]
WO WO2003041641A2 · 2003 [cited by applicant]
WO WO2003074038A1 · 2003 [cited by applicant]
WO WO2003082288A1 · 2003 [cited by applicant]
WO WO2004065354A1 · 2004 [cited by applicant]
WO WO2004069823A1 · 2004 [cited by applicant]
WO WO2004076386A2 · 2004 [cited by applicant]
WO WO2004082638A2 · 2004 [cited by applicant]
WO WO2004098609A1 · 2004 [cited by applicant]
WO WO2005000300A1 · 2005 [cited by applicant]
WO WO2005020921A2 · 2005 [cited by applicant]
WO WO2005051300A2 · 2005 [cited by applicant]
WO WO2005065681A2 · 2005 [cited by applicant]
WO WO2005066151A2 · 2005 [cited by applicant]
WO WO2005092899A1 · 2005 [cited by applicant]
WO WO2006018308A1 · 2006 [cited by applicant]
WO WO2006018309A1 · 2006 [cited by applicant]
WO WO2006044958A1 · 2006 [cited by applicant]
WO WO2006065842A2 · 2006 [cited by applicant]
WO WO2006066133A2 · 2006 [cited by applicant]
WO WO2006084186A2 · 2006 [cited by applicant]
WO WO2006087309A1 · 2006 [cited by applicant]
WO WO2007003604A2 · 2007 [cited by applicant]
WO WO2007011626A2 · 2007 [cited by applicant]
WO WO2007029035A2 · 2007 [cited by applicant]
WO WO2007056593A2 · 2007 [cited by applicant]
WO WO2007084390A2 · 2007 [cited by applicant]
WO WO2007084455A1 · 2007 [cited by applicant]
WO WO2007093827A1 · 2007 [cited by applicant]
WO WO2007098608A1 · 2007 [cited by applicant]
WO WO2007115408A1 · 2007 [cited by applicant]
WO WO2008016123A1 · 2008 [cited by applicant]
WO WO2008060721A1 · 2008 [cited by applicant]
WO WO2008064265A2 · 2008 [cited by applicant]
WO WO2008074132A1 · 2008 [cited by applicant]
WO WO2008097428A2 · 2008 [cited by applicant]
WO WO2008128335A1 · 2008 [cited by applicant]
WO WO2009011787A1 · 2009 [cited by applicant]
WO WO2009011876A1 · 2009 [cited by applicant]
WO WO2009027349A2 · 2009 [cited by applicant]
WO WO2009079011A1 · 2009 [cited by applicant]
WO WO2009129036A1 · 2009 [cited by applicant]
WO WO2009129335A2 · 2009 [cited by applicant]
WO WO2009137462A2 · 2009 [cited by applicant]
WO WO2010028192A1 · 2010 [cited by applicant]
WO WO2010033906A2 · 2010 [cited by applicant]
WO WO2010043953A2 · 2010 [cited by applicant]
WO WO2010054278A2 · 2010 [cited by applicant]
WO WO2010075551A1 · 2010 [cited by applicant]
WO WO2010078449A2 · 2010 [cited by applicant]
WO WO2010081145A1 · 2010 [cited by applicant]
WO WO2010083141A1 · 2010 [cited by applicant]
WO WO2010086311A1 · 2010 [cited by applicant]
WO WO2010088414A2 · 2010 [cited by applicant]
WO WO2010122151A1 · 2010 [cited by applicant]
WO WO2010139966A1 · 2010 [cited by applicant]
WO WO2010151318A1 · 2010 [cited by applicant]
WO WO2011002520A2 · 2011 [cited by applicant]
WO WO2011038185A2 · 2011 [cited by applicant]
WO WO2011058582A1 · 2011 [cited by applicant]
WO WO2011088181A1 · 2011 [cited by applicant]
WO WO2011088187A1 · 2011 [cited by applicant]
WO WO2011088192A1 · 2011 [cited by applicant]
WO WO2011106632A1 · 2011 [cited by applicant]
WO WO2011133888A1 · 2011 [cited by applicant]
WO WO2011133920A1 · 2011 [cited by applicant]
WO WO2011137320A2 · 2011 [cited by applicant]
WO WO2011154374A1 · 2011 [cited by applicant]
WO WO2011154431A1 · 2011 [cited by applicant]
WO WO2012012320A1 · 2012 [cited by applicant]
WO WO2012027564A1 · 2012 [cited by applicant]
WO WO2012038438A1 · 2012 [cited by applicant]
WO WO2012045804A1 · 2012 [cited by applicant]
WO WO2012047852A2 · 2012 [cited by applicant]
WO WO2012068109A2 · 2012 [cited by applicant]
WO WO2012076898A1 · 2012 [cited by applicant]
WO WO2012085038A1 · 2012 [cited by applicant]
WO WO2012088015A2 · 2012 [cited by applicant]
WO WO2012103008A1 · 2012 [cited by applicant]
WO WO2012117027A1 · 2012 [cited by applicant]
WO WO2012120023A1 · 2012 [cited by applicant]
WO WO2012123916A2 · 2012 [cited by applicant]
WO WO2012136111A1 · 2012 [cited by applicant]
WO WO2012157984A2 · 2012 [cited by applicant]
WO WO2012158957A2 · 2012 [cited by applicant]
WO WO2012170867A1 · 2012 [cited by applicant]
WO WO2013006408A1 · 2013 [cited by applicant]
WO WO2013008162A1 · 2013 [cited by applicant]
WO WO2013009810A1 · 2013 [cited by applicant]
WO WO2013009812A1 · 2013 [cited by applicant]
WO WO2013009827A1 · 2013 [cited by applicant]
WO WO2013009830A1 · 2013 [cited by applicant]
WO WO2013059582A2 · 2013 [cited by applicant]
WO WO2013062344A1 · 2013 [cited by applicant]
WO WO2013063549A1 · 2013 [cited by applicant]
WO WO2013066831A1 · 2013 [cited by applicant]
WO WO2013066832A1 · 2013 [cited by applicant]
WO WO2013066833A1 · 2013 [cited by applicant]
WO WO2013066834A1 · 2013 [cited by applicant]
WO WO2013066835A2 · 2013 [cited by applicant]
WO WO2013066836A1 · 2013 [cited by applicant]
WO WO2013066838A1 · 2013 [cited by applicant]
WO WO2013066839A2 · 2013 [cited by applicant]
WO WO2013080120A1 · 2013 [cited by applicant]
WO WO2013085890A1 · 2013 [cited by applicant]
WO WO2013101600A1 · 2013 [cited by applicant]
WO WO2013155262A2 · 2013 [cited by applicant]
WO WO2013169574A2 · 2013 [cited by applicant]
WO WO2013185353A1 · 2013 [cited by applicant]
WO WO2014014900A1 · 2014 [cited by applicant]
WO WO2014049107A1 · 2014 [cited by applicant]
WO WO2014059306A1 · 2014 [cited by applicant]
WO WO2014159210A1 · 2014 [cited by applicant]
WO WO2014159214A1 · 2014 [cited by applicant]
WO WO2014159218A1 · 2014 [cited by applicant]
WO WO2014159224A1 · 2014 [cited by applicant]
WO WO2014172191A1 · 2014 [cited by applicant]
WO WO2014178606A1 · 2014 [cited by applicant]
WO WO2014179528A2 · 2014 [cited by applicant]
WO WO2014180984A1 · 2014 [cited by applicant]
WO WO2014181137A1 · 2014 [cited by applicant]
WO WO2014194280A2 · 2014 [cited by applicant]
WO WO2014202827A1 · 2014 [cited by applicant]
WO WO2015017546A1 · 2015 [cited by applicant]
WO WO2015052160A1 · 2015 [cited by applicant]
WO WO2015058106A1 · 2015 [cited by applicant]
WO WO2015087151A1 · 2015 [cited by applicant]
WO WO2015102426A1 · 2015 [cited by applicant]
WO WO2015137750A1 · 2015 [cited by applicant]
WO WO2015154064A2 · 2015 [cited by applicant]
WO WO2015165960A1 · 2015 [cited by applicant]
WO WO2015187542A1 · 2015 [cited by applicant]
WO WO2016012485A1 · 2016 [cited by applicant]
WO WO2016018795A1 · 2016 [cited by applicant]
WO WO2016031815A1 · 2016 [cited by applicant]
WO WO2016040223A1 · 2016 [cited by applicant]
WO WO2016055786A1 · 2016 [cited by applicant]
WO WO2016087257A1 · 2016 [cited by applicant]
WO WO2016087265A1 · 2016 [cited by applicant]
WO WO2016100619A2 · 2016 [cited by applicant]
WO WO2016105518A1 · 2016 [cited by applicant]
WO WO2016120182A1 · 2016 [cited by applicant]
WO WO2016126721A1 · 2016 [cited by applicant]
WO WO2016126722A1 · 2016 [cited by applicant]
WO WO2016126724A1 · 2016 [cited by applicant]
WO WO2016126725A1 · 2016 [cited by applicant]
WO WO2016126726A1 · 2016 [cited by applicant]
WO WO2016128541A1 · 2016 [cited by applicant]
WO WO2016168598A1 · 2016 [cited by applicant]
WO WO2016168660A1 · 2016 [cited by applicant]
WO WO2016179550A1 · 2016 [cited by applicant]
WO WO2016179554A1 · 2016 [cited by applicant]
WO WO2016183331A1 · 2016 [cited by applicant]
WO WO2016190630A1 · 2016 [cited by applicant]
WO WO2016196771A1 · 2016 [cited by applicant]
WO WO2017011323A1 · 2017 [cited by applicant]
WO WO2017014321A1 · 2017 [cited by applicant]
WO WO2017018803A1 · 2017 [cited by applicant]
WO WO2017018804A1 · 2017 [cited by applicant]
WO WO2017018805A1 · 2017 [cited by applicant]
WO WO2017023133A2 · 2017 [cited by applicant]
WO WO2017024009A1 · 2017 [cited by applicant]
WO WO2017029514A1 · 2017 [cited by applicant]
WO WO2017033946A1 · 2017 [cited by applicant]
WO WO2017060854A1 · 2017 [cited by applicant]
WO WO2017065473A1 · 2017 [cited by applicant]
WO WO2017076757A1 · 2017 [cited by applicant]
WO WO2017081310A1 · 2017 [cited by applicant]
WO WO2017081311A1 · 2017 [cited by applicant]
WO WO2017083368A1 · 2017 [cited by applicant]
WO WO2017093019A1 · 2017 [cited by applicant]
WO WO2017109044A1 · 2017 [cited by applicant]
WO WO2017110861A1 · 2017 [cited by applicant]
WO WO2017110862A1 · 2017 [cited by applicant]
WO WO2017111152A1 · 2017 [cited by applicant]
WO WO2017123568A2 · 2017 [cited by applicant]
WO WO2017142883A1 · 2017 [cited by applicant]
WO WO2017156350A1 · 2017 [cited by applicant]
WO WO2017162834A1 · 2017 [cited by applicant]
WO WO2017165256A1 · 2017 [cited by applicant]
WO WO2017190109A1 · 2017 [cited by applicant]
WO WO2017193030A1 · 2017 [cited by applicant]
WO WO2017197046A1 · 2017 [cited by applicant]
WO WO2017208032A1 · 2017 [cited by applicant]
WO WO2017213252A1 · 2017 [cited by applicant]
WO WO2017222950A1 · 2017 [cited by applicant]
WO WO2017222951A1 · 2017 [cited by applicant]
WO WO2017222952A1 · 2017 [cited by applicant]
WO WO2018005192A1 · 2018 [cited by applicant]
WO WO2018050656A2 · 2018 [cited by applicant]
WO WO2018055135A1 · 2018 [cited by applicant]
WO WO2018075959A1 · 2018 [cited by applicant]
WO WO2018085170A1 · 2018 [cited by applicant]
WO WO2018129533A1 · 2018 [cited by applicant]
WO WO2018154466A1 · 2018 [cited by applicant]
WO WO2018165520A1 · 2018 [cited by applicant]
WO WO2018187553A1 · 2018 [cited by applicant]
WO WO2018188962A1 · 2018 [cited by applicant]
WO WO2018189340A1 · 2018 [cited by applicant]
WO WO2018191360A1 · 2018 [cited by applicant]
WO WO2018202491A1 · 2018 [cited by applicant]
WO WO2018213364A1 · 2018 [cited by applicant]
WO WO2018219356A1 · 2018 [cited by applicant]
WO WO2019027054A1 · 2019 [cited by applicant]
WO WO2019060210A1 · 2019 [cited by applicant]
WO WO2019100735A1 · 2019 [cited by applicant]
WO WO2019101709A1 · 2019 [cited by applicant]
WO WO2019109046A1 · 2019 [cited by applicant]
WO WO2019110663A1 · 2019 [cited by applicant]
WO WO2019122323A1 · 2019 [cited by applicant]
WO WO2019139921A1 · 2019 [cited by applicant]
WO WO2019164222A1 · 2019 [cited by applicant]
WO WO2019166824A1 · 2019 [cited by applicant]
WO WO2019171234A1 · 2019 [cited by applicant]
WO WO2019200238A1 · 2019 [cited by applicant]
WO WO2019204550A1 · 2019 [cited by applicant]
WO WO2019212927A1 · 2019 [cited by applicant]
WO WO2019228289A1 · 2019 [cited by applicant]
WO WO2020011816A1 · 2020 [cited by applicant]
WO WO2020022794A1 · 2020 [cited by applicant]
WO WO2020028150A1 · 2020 [cited by applicant]
WO WO2020029908A1 · 2020 [cited by applicant]
WO WO2020039028A1 · 2020 [cited by applicant]
WO WO2020061112A1 · 2020 [cited by applicant]
WO WO2020061118A1 · 2020 [cited by applicant]
WO WO2020061216A1 · 2020 [cited by applicant]
WO WO2020070610A1 · 2020 [cited by applicant]
WO WO2020096916A2 · 2020 [cited by applicant]
WO WO2020106119A1 · 2020 [cited by applicant]
WO WO2020127974A1 · 2020 [cited by applicant]
WO WO2020132561A1 · 2020 [cited by applicant]
WO WO2020158762A1 · 2020 [cited by applicant]
WO WO2020194272A1 · 2020 [cited by applicant]
WO WO2020201773A1 · 2020 [cited by applicant]
WO WO2020207941A1 · 2020 [cited by applicant]
WO WO2020212479A1 · 2020 [cited by applicant]
WO WO2020219650A1 · 2020 [cited by applicant]
WO WO2020223136A1 · 2020 [cited by applicant]
WO WO2020240492A1 · 2020 [cited by applicant]
WO WO2020240493A1 · 2020 [cited by applicant]
WO WO2020245381A1 · 2020 [cited by applicant]
WO WO2020254494A1 · 2020 [cited by applicant]
WO WO2020264437A1 · 2020 [cited by applicant]
WO WO2021021979A2 · 2021 [cited by applicant]
WO WO2021022076A1 · 2021 [cited by applicant]
WO WO2021046183A1 · 2021 [cited by applicant]
WO WO2021048242A1 · 2021 [cited by applicant]
WO WO2021057872A1 · 2021 [cited by applicant]
WO WO2021060567A1 · 2021 [cited by applicant]
WO WO2021067859A1 · 2021 [cited by applicant]
WO WO2021092151A1 · 2021 [cited by applicant]
WO WO2021092153A1 · 2021 [cited by applicant]
WO WO2021092174A1 · 2021 [cited by applicant]
WO WO2021127643A1 · 2021 [cited by applicant]
WO WO2021133957A1 · 2021 [cited by applicant]
WO WO2021172886A1 · 2021 [cited by applicant]
WO WO2021172887A1 · 2021 [cited by applicant]
WO WO2021208945A1 · 2021 [cited by applicant]
WO WO2021210857A1 · 2021 [cited by applicant]
WO WO2021236491A1 · 2021 [cited by applicant]
WO WO2021244416A1 · 2021 [cited by applicant]
WO WO2021263171A1 · 2021 [cited by applicant]
WO WO2022013728A1 · 2022 [cited by applicant]
WO WO2022029041A1 · 2022 [cited by applicant]
WO WO2022049496A1 · 2022 [cited by applicant]
WO WO2022081928A1 · 2022 [cited by applicant]
WO WO2022133551A1 · 2022 [cited by applicant]
WO WO2022174193A1 · 2022 [cited by applicant]
WO WO2022187690A1 · 2022 [cited by applicant]
WO WO2022197690A1 · 2022 [cited by applicant]
WO WO2022215020A1 · 2022 [cited by applicant]
WO WO2022216616A1 · 2022 [cited by applicant]
WO WO2022226388A1 · 2022 [cited by applicant]
WO WO2022235842A1 · 2022 [cited by applicant]
WO WO2023081328A1 · 2023 [cited by applicant]
WO WO2023097386A1 · 2023 [cited by applicant]
WO WO2023118507A2 · 2023 [cited by applicant]
WO WO2023154758A1 · 2023 [cited by applicant]
WO WO2023195809A1 · 2023 [cited by applicant]
WO WO2023198172A1 · 2023 [cited by applicant]
WO WO2024013690A1 · 2024 [cited by applicant]
WO WO2024017897A1 · 2024 [cited by applicant]
Invitation to Pay Additional Fees mailed Sep. 24, 2020 for Application No. PCT/US2020/044148. [cited by applicant]
International Search Report and Written Opinion mailed Feb. 16, 2021 for Application No. PCT/US2020/044148. [cited by applicant]
International Preliminary Report on Patentability mailed Feb. 10, 2022 for Application No. PCT/US2020/044148. [cited by applicant]
International Search Report and Written Opinion mailed May 10, 2018 for Application No. PCT/US2018/021696. [cited by applicant]
International Preliminary Report on Patentability mailed Sep. 19, 2021 for Application No. PCT/US2018/021696. [cited by applicant]
Invitation to Pay Additional Fees mailed Apr. 29, 2022 for Application No. PCT/US2022/015129. [cited by applicant]
International Search Report and Written Opinion mailed Jun. 24, 2022 for Application No. PCT/US2022/015129. [cited by applicant]
Invitation to Pay Additional Fees mailed Jun. 9, 2023 for Application No. PCT/US2023/017900. [cited by applicant]
[No Author Listed], 2-(Difluoromethyl)-5-[2-(4-fluorophenoxy)pyrimidin-5-yl]-1,3,4-oxadiazole. PubChem CID No. 162351258. Accessed May 25, 2023. Created Dec. 13, 2021. https://pubchem.ncbi.nlm.nih.gov/compound/162351258… [cited by applicant]
[No Author Listed], 2-(Phenoxymethyl)pyrimidine. PubChem CID No. 19371420. Accessed May 25, 2023. Created Dec. 4, 2017. https://pubchem.ncbi.nlm.nih.gov/compound/19371420. 11 pages. [cited by applicant]
[No Author Listed], Bringing NHA HDAC6 inhibitors to the clinic for cardiovascular and neurodegenerative disorders. Chong Kun Dang Pharmaceutical Corp. Nature Research Custom Media. Jun. 2022;B41. [cited by applicant]
[No Author Listed], Cancer Innovates, accelerating early cancer drug discovery. Cancer Innova. Feb. 2022. Accessed from <https://www-cancerinnova-com.translate.goog/en/cancer-innova-acelerando-el-descubrimiento-temprano… [cited by applicant]
[No Author Listed], CAS Registration No. 1332894-18-4. Registry (STN). Sep. 20, 2011. 1 page. [cited by applicant]
[No Author Listed], CAS Registration No. 1860746-44-6. Registry (STN). Feb. 5, 2016. 1 page. [cited by applicant]
[No Author Listed], CAS Registration No. 1875612-53-5. Registry (STN). Feb. 28, 2016. 1 page. [cited by applicant]
[No Author Listed], CAS Registration No. 73779-41-6. Registry (STN). Nov. 16, 1984. 1 page. [cited by applicant]
[No Author Listed], CAY10603: Catalog No. S7596; Synonyms: BML-281. Apr. 2015. 4 pages. Accessed Jul. 19, 2022 from <https://www.selleckchem.com/products/cay10603.html?gclid=CjwKCAjwoMSWBhAdEiwAVJ2ndv0I8KYzzn0XiWLIF5DRM… [cited by applicant]
[No Author Listed], HDAC: Inhibitory Selectivity. AdooQ Bioscience. 21 pages. Accessed May 18, 2022 from <https://www.adooq.com/epigenetics-histone-deacetylase-hdac.html?gclid=EAIaIQobChMI4K_CiJzk9AIVpQaICR2_rgPTEAMYASA… [cited by applicant]
[No Author Listed], Augustine Therapeutics Showcase Presentation. Recorded at the 2022 Investival Showcase in London, England on Nov. 14, 2022. Accessed Feb. 7, 2023 from <https://www.youtube.com/watch?v=8wJXGd2CgQU>. S… [cited by applicant]
[No Author Listed], Jubilant Therapeutics Inc. receives Orphan Drug Designation for JBI-802 for Acute Myeloid Leukemia (AML) and Small Cell Lung Cancer (SCLC). Jubilant Therapeutics. Jan. 5, 2023. Accessed from <https:/… [cited by applicant]
[No Author Listed], NCT03713892: CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects. Last Update Posted Feb. 24, 2020. 6 pages. Accessed Feb. 7, 2023 from <https://clinicaltrials.gov/c… [cited by applicant]
[No Author Listed], NCT04746287: Evaluation of the Safety and Tolerability of CKD-510 in Healthy Subjects. Last Update Posted May 4, 2022. 8 pages. Accessed Feb. 7, 2023 from <https://clinicaltrials.gov/ct2/show/NCT0474… [cited by applicant]
[No Author Listed], NCT05526742: A Study to Evaluate the Relative Bioavailability of Formulations of CKD-510 and to Assess the Effect of Food on the CKD-510 Tablet Formulation in Healthy Subjects. Last Update Posted Sep… [cited by applicant]
[No Author Listed], OnKure Expands Executive Team with the Addition of Chief Scientific Officer and Chief Development Officer. OnKure Therapeutics. Aug. 3, 2021. Accessed from <https://onkuretherapeutics.com/press-relea… [cited by applicant]